Effects of raloxifene on bone mineral metabolism in postmenopausal Japanese women on hemodialysis.

Abstract

In addition to renal osteodystrophy, postmenopausal women on hemodialysis are at high risk for osteoporosis. Recent studies reported the effects of raloxifene, a selective estrogen receptor modulator for osteoporosis, in postmenopausal women. The present study evaluated the efficacy of raloxifene and its effects on bone mineral metabolism in postmenopausal Japanese patients on dialysis. In a prospective, multicentre study, 17 postmenopausal women on chronic hemodialysis with severe osteoporosis (bone mineral density [BMD]≤2 SD by bone densitometry) were treated with 60 mg/day raloxifene hydrochloride for 12 months. The study also included 10 age-matched control women. Vitamin D and calcium salts were not changed during the study. Intact parathyroid hormone (iPTH), serum calcium and phosphorus, and bone resorption marker (NTx) were measured, and BMD were determined by DEXA, at 0, 6, and 12 months after administration of raloxifene. The mean lumbar spine BMD at baseline was similar in the two groups. Raloxifene therapy (for 12 months) improved lumbar spine BMD (by 2.6%) in 53% of the patients, while 70% of the control group showed a reduction in BMD (by 4.0%). Raloxifene significantly decreased serum calcium and increased iPTH. Our results suggested that raloxifene improved trabecular BMD in postmenopausal Japanese women on hemodialysis. The effects of raloxifene on serum calcium and serum iPTH level suggest it improves bone resorption. Vitamin D and/or calcium salts should be added to raloxifene treatment to avoid secondary hyperparathyroidism.

• Authors: Motoko Tanaka, Kazuko Itoh, Kazunori Matsushita, Kazutaka Matsushita, Misaki Moriishi, Hideki Kawanishi, Masafumi Fukagawa
• Journal: Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy (Ther Apher Dial) Vol. 15 Suppl 1 Pg. 62-6 (Jun 2011) ISSN: 1744-9987 [Electronic] Australia
• PMID: 21595855 (Publication Type: Journal Article, Multicenter Study)
• Copyright: © 2011 The Authors. Therapeutic Apheresis and Dialysis © 2011 International Society for Apheresis.

Chemical References

• Bone Density Conservation Agents
• Collagen Type I
• Peptides
• collagen type I trimeric cross-linked peptide
• Phosphorus
• Raloxifene Hydrochloride
• Calcium

Topics

• Absorptiometry, Photon
• Aged
• Asian People
• Bone Density (drug effects)
• Bone Density Conservation Agents (therapeutic use)
• Calcium (blood)
• Case-Control Studies
• Collagen Type I (blood)
• Female
• Humans
• Middle Aged
• Osteoporosis, Postmenopausal (drug therapy, etiology)
• Peptides (blood)
• Phosphorus (blood)
• Postmenopause
• Prospective Studies
• Raloxifene Hydrochloride (therapeutic use)
• Renal Dialysis
• Severity of Illness Index
• Time Factors